Unicycive Therapeutics (UNCY) Net Income towards Common Stockholders (2020 - 2026)
Unicycive Therapeutics posted quarterly Net Income towards Common Stockholders of -$12.8 million for Q1 2026, down 2614.51% year-on-year from $510000.0 in Q1 2025, and up 12.57% on a QoQ basis from -$14.7 million in Q4 2025.
Unicycive Therapeutics (UNCY) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$12.8 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 2614.51% year-over-year to -$12.8 million; the trailing twelve-month figure through Mar 2026 stood at -$39.9 million (down 81.03% YoY), and the FY2025 full-year result was -$26.6 million, up 29.79% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$12.8 million, up from -$14.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $3.0 million in Q2 2024 and bottomed at -$21.5 million in Q4 2024.
- The 5-year median for Net Income towards Common Stockholders is -$5.6 million (2022), against an average of -$7.8 million.
- The widest annual swing landed in 2024, when Net Income towards Common Stockholders jumped 168.52%; it then tumbled 2614.51% in 2026.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$5.3 million in 2022, then plunged by 46.36% to -$7.8 million in 2023, then sank by 176.03% to -$21.5 million in 2024, then jumped by 31.86% to -$14.7 million in 2025, then rose by 12.57% to -$12.8 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$12.8 million (Q1 2026), -$14.7 million (Q4 2025), and -$6.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | -12.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.82 Mn |
| Dec 31, 2025 | -14.67 Mn |
| Sep 30, 2025 | -6.01 Mn |
| Jun 30, 2025 | -6.45 Mn |
| Mar 31, 2025 | 510,000.00 |
| Dec 31, 2024 | -21.53 Mn |
| Sep 30, 2024 | -4.10 Mn |
| Jun 30, 2024 | 3.04 Mn |
| Mar 31, 2024 | -21.17 Mn |
| Dec 31, 2023 | -7.80 Mn |
| Sep 30, 2023 | -4.41 Mn |
| Jun 30, 2023 | -4.44 Mn |
| Mar 31, 2023 | -14.77 Mn |
| Dec 31, 2022 | -5.33 Mn |
| Sep 30, 2022 | -5.56 Mn |
| Jun 30, 2022 | -3.64 Mn |
| Mar 31, 2022 | -3.54 Mn |
| Dec 31, 2021 | -2.75 Mn |
| Sep 30, 2021 | -5.20 Mn |
| Jun 30, 2021 | -1.10 Mn |
| Mar 31, 2021 | -983,000.00 |
| Dec 31, 2020 | -880,000.00 |
| Sep 30, 2020 | -702,000.00 |
| Jun 30, 2020 | -338,000.00 |